Replimune competitors and similar companiesClear all
Replimune's competitors and similar companies include 3sbio, Kyowa Kirin and Acerta Pharma.
 Kyowa Kirin Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system. | ||||
Founding Date | Founding Date 2015 | Founding Date 1993 | Founding Date 2008 | Founding Date 2013 |
Type | Type Public | Type Public | Type Public | Type Subsidiary |
Tags | ||||
Locations | Locations Woburn, US HQ Milton, GB Woburn, US | Locations Shenyang, CN HQ | Locations South San Francisco, US HQ Oss, NL Oss, NL | |
Employees | Employees 10422% increase | Employees 5,2325% decrease | Employees 5,752 | Employees 197 |
Valuation ($) | Valuation ($) 1.1 b | Valuation ($) N/A | Valuation ($) 11.2 b | Valuation ($) N/A |
Employee Rating | Employee Rating 3.3 | Employee Rating 3 | Employee Rating N/A | Employee Rating 3.5 |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) ¥6.4b (FY, 2021) | Revenue (est.) ¥398.4b (FY, 2022) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods ¥777.3m (FY, 2021) | Cost of goods ¥68.4b (FY, 2022) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit ¥5.7b (FY, 2021) | Gross profit ¥331.6b (FY, 2022) | Gross profit N/A |
Net income | Net income ($118m) (FY, 2022) | Net income ¥1.6b (FY, 2021) | Net income ¥53.6b (FY, 2022) | Net income N/A |
Funding | ||||
Total funding raised | Total funding raised $ 30m | Total funding raised $ 15.2m | Total funding raised N/A | Total funding raised $ 60m |
For sources of this data, please see the company profile
View company profiles
3sbio
HQ
Shenyang, CN
Employees
5,232↓ 5% decrease
3sbio (三生制药集团) is a company that develops biopharmaceuticals.
View companyKyowa Kirin
HQ
Tokyo, JP
Employees
5,752
Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system.
View company